FDA Follow-On Biologics Guidance Will Have Broad Scope, But Not "Break New Ground"
This article was originally published in The Pink Sheet Daily
Executive Summary
Acting CDER Director Galson says draft guidance will be out this spring. Scientific principles will cover range of biologics therapies – but scientific and legal obstacles will limit impact to a relative handful of products.
You may also be interested in...
FDA Follow-On Biologics Public Meeting Slated For Early 2005
Projected timing of the meeting suggests that release of a draft guidance will not occur until at least a year after FDA’s original projected timeframe of spring 2004.
FDA Follow-On Biologics Public Meeting Slated For Early 2005
Projected timing of the meeting suggests that release of a draft guidance will not occur until at least a year after FDA’s original projected timeframe of spring 2004.
"Generic" Biologics Hearing Set By Sen. Hatch; FDA Expected To Testify
Witnesses at June 23 hearing are expected to include Acting Commissioner Crawford and Chief Counsel Troy, as well as representatives from the generic and biotech industries.